D-1364-2019 Class II Terminated
FDA drug recall D-1364-2019 was initiated by Torrent Pharma Inc on May 21, 2019 and is designated Class II. Reason for recall: cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii). The recall status is terminated (terminated Oct 6, 2020). Affected quantity: 6,000 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jun 19, 2019
- Initiation Date
- May 21, 2019
- Termination Date
- Oct 6, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 6,000 bottles
Product description
Guaifenesin DAC Oral Solution, Sugar free, (Guaifenesin, Pseudoephedrine HCl and Codeine Phosphate Oral Solution, USP), Expectorant, Nasal Decongestant, Cough Suppressant, 100 mg/30 mg/10 mg per 5 mL, One Pint (473 mL) bottle, NDC: 16571-301-16, Manufactured by Bio-Pharm Inc., Levittown, PA 19057, Distributed by Rising Pharmaceuticals Inc., Allendale, NJ 07401.
Reason for recall
cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).
Distribution pattern
Product was distributed to 9 distributors, direct accounts and relabelers who may have further distributed the product throughout the United States.
Code information
Lot #s: 17E031, Exp. 05/2019; 18F030, Exp. 06/2020.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1364-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026